A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 181 participants.

Also called NCT02368652

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 181 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02368652
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02368652. Randomized; quadruple masking; primary purpose treatment. Start 2014-12 (actual); primary completion 2015-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy
Condition
Essential Hypertension
Intervention (Drug)
Candesartan cilexetil 16mg
Intervention (Drug)
Amlodipine 10mg, Candesartan cilexetil 16mg
Lead sponsor
HK inno.N Corporation (class: industry)

Record details

Record id
cardio:ct-nct02368652
Content hash
3b7457f757df44b7ae84679d4dbb12cd775aeb3984603d71f2af3f1a4f0527da